214 related articles for article (PubMed ID: 28487999)
1. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
Otake A; Tsuji D; Taku K; Kawasaki Y; Yokoi M; Nakamori H; Osada M; Matsumoto M; Inoue K; Hirai K; Itoh K
Eur J Clin Pharmacol; 2017 Aug; 73(8):1033-1039. PubMed ID: 28487999
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Kan M; Imaoka H; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Umemoto K; Kimura G; Suzuki Y; Eguchi H; Otsuru T; Goda K; Ikeda M
Cancer Chemother Pharmacol; 2020 Aug; 86(2):203-210. PubMed ID: 32632515
[TBL] [Abstract][Full Text] [Related]
3. Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.
Yamamoto K; Sasano T; Tsuji D; Ishizuka Y; Tokou U; Nakamichi H; Yoneda T; Shiokawa M; Yabe K
Ann Pharmacother; 2019 Jul; 53(7):690-696. PubMed ID: 30734587
[TBL] [Abstract][Full Text] [Related]
4. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer.
Kurihara T; Kogo M; Ishii M; Shimada K; Yoneyama K; Kitamura K; Shimizu S; Yoshida H; Kiuchi Y
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1217-24. PubMed ID: 26560484
[TBL] [Abstract][Full Text] [Related]
6. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
[TBL] [Abstract][Full Text] [Related]
7. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.
Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Hagihara A; Iwasa S; Kojima Y
Jpn J Clin Oncol; 2008 Nov; 38(11):755-61. PubMed ID: 18845521
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
Park I; Choi SJ; Kim YS; Ahn HK; Hong J; Sym SJ; Park J; Cho EK; Lee JH; Shin YJ; Shin DB
Cancer Res Treat; 2016 Oct; 48(4):1264-1273. PubMed ID: 27034148
[TBL] [Abstract][Full Text] [Related]
10. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Hashimoto K; Ueno H; Ikeda M; Kojima Y; Hagihara A; Kondo S; Morizane C; Okusaka T
Oncology; 2009; 77(3-4):217-23. PubMed ID: 19729980
[TBL] [Abstract][Full Text] [Related]
11. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
Sawaki A; Kanemitsu Y; Mizuno N; Takahashi K; Nakamura T; Ioka T; Tanaka S; Nakaizumi A; Salem AA; Ueda R; Yamao K
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1292-7. PubMed ID: 18700899
[TBL] [Abstract][Full Text] [Related]
12. Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Roviello G; Ramello M; Catalano M; D'Angelo A; Conca R; Gasperoni S; Dreoni L; Petrioli R; Ianza A; Nobili S; Aieta M; Mini E
Sci Rep; 2020 Nov; 10(1):19281. PubMed ID: 33159172
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].
Moriwaki T; Hyodo I; Nishina T; Nasu J; Hidaka S; Kajiwara T; Tsuzuki T; Hirao K; Tsubouchi E; Yamauchi Y; Hirasaki S; Masumoto T; Tanada M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1373-6. PubMed ID: 15446559
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
An SG; Kim DU; Song GA; Jang AL
Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.
Nakachi K; Furuse J; Ishii H; Suzuki E; Yoshino M
Jpn J Clin Oncol; 2007 Feb; 37(2):114-20. PubMed ID: 17272317
[TBL] [Abstract][Full Text] [Related]
17. Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy.
Chen Y; Shi Y; Yan H; Wang YR; Dai GH
Oncotarget; 2017 Sep; 8(39):66593-66600. PubMed ID: 29029540
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
19. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients.
Jang SH; Kim SY; Kim JH; Park S; Hwang YI; Kim DG; Jung KS
J Cancer Res Clin Oncol; 2013 Mar; 139(3):409-17. PubMed ID: 23124139
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
